



**HAL**  
open science

## Use of $5\alpha$ -reductase inhibitors for benign prostate hypertrophy and risk of high-grade prostate cancer A French population-based study

Lucie-Marie Scailteux, Nathalie Rioux-Leclercq, Sebastien Vincendeau, Frédéric Balusson, Emmanuel Nowak, Emmanuel Oger

### ► To cite this version:

Lucie-Marie Scailteux, Nathalie Rioux-Leclercq, Sebastien Vincendeau, Frédéric Balusson, Emmanuel Nowak, et al.. Use of  $5\alpha$ -reductase inhibitors for benign prostate hypertrophy and risk of high-grade prostate cancer A French population-based study. *BJU International*, 2019, 123 (2), pp.293-299. 10.1111/bju.14495 . hal-01863270

**HAL Id: hal-01863270**

**<https://univ-rennes.hal.science/hal-01863270v1>**

Submitted on 13 Sep 2018

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

DR. LUCIE-MARIE SCAILTEUX (Orcid ID : 0000-0001-7047-9107)

Article type : Original Article

Article Category: Urological Oncology

**Use of 5 $\alpha$ -reductase inhibitors for benign prostate hypertrophy and risk of high-grade prostate cancer: A French population-based study**

SCAILTEUX Lucie-Marie<sup>1,2</sup> (PharmD, PhD), RIOUX-LECLERCQ Nathalie<sup>3,4</sup> (MD, PhD), VINCEDEAU Sébastien<sup>5</sup> (MD), BALUSSON Frédéric<sup>2</sup> (Statistician), NOWAK Emmanuel<sup>6</sup> (PhD, Senior statistician), OGER Emmanuel<sup>1,2</sup> (MD, PhD), and the Network of Pathologist in Brittany (list below\*).

1. Pharmacovigilance, Pharmacoepidemiology and Drug Information Centre, Department of Clinical Pharmacology, Rennes University Hospital, 35033 Rennes, France
2. Univ Rennes, EA 7449 REPERES 'Pharmacoepidemiology and Health Services Research', F 35000 Rennes, France
3. Pathology Department, Rennes University Hospital, Rennes, France
4. Inserm, UMR 1085 – IRSET, Rennes University, France
5. Urology Department, Rennes University Hospital, Rennes, France
6. Université de Bretagne Loire, Université de Brest, INSERM CIC 1412, CHRU de Brest, France

\*Network of pathologists: M. DOUCET; HAINRY, BROYER-PETIT & BEYLS-NOEL; COEUGNET, GIRARDOT, GOLLAIRE, TISSEAU & HOGENHUIS; PERROT, MOREAU & STAROZ; M. TAS; M. SAOUT; M. POLITIS.

Corresponding author email address: [luciemarie.scailteux@chu-rennes.fr](mailto:luciemarie.scailteux@chu-rennes.fr)

Address: CRPV, Hôpital Pontchaillou, CHU Rennes, rue Henri Le Guilloux, 35033 Rennes Cedex 9.

Phone: +33 2 99 28 43 63 / Fax : +33 2 99 28 24 26

Funding: This work was supported by the Fondation pour la Recherche Médicale (FRM), grant number IMD-2013-1228948, to Emmanuel OGER and Nathalie RIOUX-LECLERCQ. FRM had no role in the study design, collection, analysis, and interpretation of data; nor in the writing of the report; nor in the decision to submit the article for publication. All investigators state their independence from funder.

Key words: Benign prostate hypertrophy, prostate cancer, 5 alpha reductase inhibitors, alpha blockers, population based-study.

#### **Structured abstract**

Background – To assess the association between 5 $\alpha$ -reductase inhibitor (5-ARI) use and high grade (Gleason score 8-10) prostate cancer.

Methods – We set up a population-based nested matched case-control study using the French Health Insurance Database linked to data from all Brittany (France) path labs. Among 74,596 men with  $\geq 1$  drug reimbursement for symptomatic benign prostate hypertrophy

between January 1, 2010 through December 31, 2011, 767 incident prostate cancer cases between January 1, 2012 through December 31, 2013 were matched on age and delay between the first observed delivery of drug for benign prostate hypertrophy (5-ARI, alpha-blockers or phytotherapy) and diagnostic date of the case to five controls, using an incidence density sampling design.

Results - 963 men (153 cases, 810 controls) had been exposed to 5-alpha reductase inhibitors. A statistically significant heterogeneity ( $p = 0.0048$ ) was detected across cancer grades when estimating association between prostate cancer and 5-alpha reductase inhibitors long term use ( $\geq 2$  years) versus no 5-alpha reductase inhibitor exposure: adjusted conditional odds ratio was 1.76 [0.97-3.21] for Gleason  $\geq 8$ , and 0.64 [0.44-0.93] for Gleason  $< 8$ .

Interpretation - Our results supported an increased risk for high-grade and a decreased risk for low-grade prostate cancer. Patients treated for longer than 2 years with 5-alpha reductase inhibitors should be informed of increased risk for the development of high-grade disease.

ClinicalTrials.gov identifier: NCT02873117.

### **Abbreviations**

5-ARI: 5-alpha-reductase inhibitors

BPH: benign prostate hypertrophy

ICD-10 codes: International Classification of Diseases, 10<sup>th</sup> edition

LTD: long-term disease

OR: odds ratio

PCPT: Prostate Cancer Prevention Trial

PSA: prostate specific antigen

REDUCE: Reduction by Dutasteride of Prostate Cancer Events

RR: risk ratio

## **Introduction**

With a high prevalence(1), a risk of morbidity from treatment(2) or from active surveillance with follow-up biopsies(3), primary prevention of prostate cancer is attractive. Two large randomized trials(4,5) have demonstrated that 5-alpha-reductase inhibitors (5-ARI) reduced overall prostate cancer risk by 20% to 25%, but they also reported a statistically significant increased risk of high-grade cancer (Gleason scores 7-10) and so far the use of 5-ARI is not recommended for primary prevention(6–8). Reason for the observed increased risk is controversial(9) including false result through detection bias(10,11).

Treatment with 5-ARI has clear benefits for men with lower urinary tract symptoms related to benign prostate hypertrophy(12,13). In those men, no difference was observed regarding the number of Gleason score 8-10 cancers in men allocated to dutasteride compared to those allocated to tamsulosin(14). Though three observational studies(15–17) reported somehow reassuring results, these findings did not rule out an increased risk of high-grade prostate cancer. Considering that the association between 5-ARI use and high-grade prostate cancer is still debated, we set up the CANARI study investigating the association

between 5-ARI use and prostate cancer according to Gleason score ( $< 8$  or  $\geq 8$ ), compared to 5-ARI non-users.

## **Patients and Methods**

**Study design, setting and participants.** This population-based matched case-control study used data (2010 to 2013) from the comprehensive French Health Insurance Data (SNIIRAM) linked to data from all path labs located in Brittany, France.

Design description and linkage methodology were reported elsewhere(18). Among men living in Brittany, all treated for symptomatic or complicated BPH in 2010-2011 (Supplementary Table S1), we identified incident cases of prostate cancer in 2012-2013 (Supplementary Table S2) and confirmed the diagnosis by linkage to pathology results (Gleason score). We then defined: men with high-grade prostate cancer (Gleason score  $\geq 8$ ) and men with low-grade prostate cancer (Gleason score  $< 8$ ). To be eligible, a case had to have a delay of at least one year between the first observed delivery of drug for BPH and prostate cancer diagnosis. Figure 1 displays a flowchart. For each case, five controls alive and free of prostate cancer at diagnosis date of the case (index date) were randomly selected from the cohort. They were matched on age and delay between the first observed delivery of drug for BPH and index date through an incidence density sampling design.

**Exposure.** We defined “5-ARI users” as patients having at least two deliveries; the others were categorized as “5-ARI non-users” (Supplementary Table S1). Exposure was quantified by the cumulative duration of 5-ARI dispensed calculated from all data observed (backward from index date to January 1<sup>st</sup>, 2010) and categorized for sake of clarity into three classes (less than 1 year, [1-2[ and  $\geq 2$  years).

**Variables and sources of data.** Using SNIIRAM data(19), we classified cases and controls as having or not some pre-specified comorbidities (Supplementary Table S2). We also obtained dates of performed transurethral resections, prostate biopsy procedures, and PSA measurements (results unavailable). On the 2010-2013 period, French guidelines as regards prostate biopsies were the same as European guidelines which recommend 10 to 12 biopsy cores but not more than 12 (20,21). In Brittany pathology laboratories, 12 biopsy cores are usually sent for analysis.

**Study size.** At a 5% two-sided significance level, upon the hypothesis of 5-ARI exposure frequency of 20% among controls(22), 98 cases of high grade prostate cancer and 490 controls (1:5 case-to-control ratio) allowed to detect an odds ratio of 2.0 with 80% power, keeping in mind that matching improves power though in an unknown manner.

**Statistical methods.** Characteristics of patients were described according to their case-control status. Measure of association used odds ratio (and 95% confidence interval) through conditional logistic regression to take into account matching. Multivariate conditional logistic regression analysis was performed to further adjust on potential risk factors. As PSA measurement and number of prostate samples (biopsy or transurethral resection) were potentially in the causal pathway leading to prostate cancer, a sensitivity analysis without adjustment on those parameters was also made.

Association between prostate cancer and 5-ARI exposure was expected to be different whenever low-grade or high-grade cancer was considered. An interaction term between exposure and prostate cancer grade was introduced in the logistic model in order to allow different association strength according to the considered individual outcome (low or high-grade prostate cancer) and to test homogeneity across these individual components of the

composite outcome(23). A sensitivity analysis was made according to the recently proposed new five-tiered Gleason grade groups (GGGs)(24).

Statistical analyses used the LOGISTIC procedure of the SAS software version 9.4 (SAS Institute Inc, Cary, NC) with a STRATA statement.

**Ethical considerations.** The study got regulatory approval (CNIL: DR-2014-084); ClinicalTrials.gov identifier: NCT02873117.

## Results

**Participants.** Among 74,596 eligible men, 859 cases of confirmed prostate cancer were identified in 2012-2013 (Figure 1); 767 cases (including 153 “5-ARI users”) were available for the analysis, matched to 3835 controls (including 810 “5-ARI users”).

**Descriptive data.** After matching, mean age was 69.3 years, and men with Gleason scores < 8 were younger than those with Gleason  $\geq$  8 (mean age 68.2 versus 76.0 years) (table 1). All cases had at least one prostate sample before the index date compared to 10.6 % in controls. Cases had more frequently more than one PSA measurement than in controls (96.5 % vs. 82.4 %). Excluding the biopsy which made the diagnosis, 71.9 % of cases and 3.7 % of matched controls had at least 1 one another biopsy before diagnosis; 25.4 % of cases and 6.7 % of matched controls had TURP. Cases and controls were not markedly different as regards measured co-morbidities.

**Exposure data.** 153 (20.0 %) cases and 810 (21.1%) controls were “5-ARI users” before index date and 400 men had a duration of use of 5-ARI  $\geq$  2 years: 58 were cases (including 38 with Gleason < 8 and 20 with Gleason  $\geq$  8) and 342 were controls (Supplementary Table S3). When comparing “5-ARI users” to “5-ARI non-users”, no substantial differences were observed, including PSA measurement and prostate samples (table 2). Most of “5-ARI non-



users" received alpha-adrenoreceptor antagonists (Tamsulosin, 35 %; Alfuzosin, 24 %), but also *Serenoas repens* (22 %) and *Pygeum africanum* (11 %).

**Main results.** Matched unadjusted estimates and confounder-adjusted estimates are shown in Figure 2 and Supplementary Table S3. Conditional adjusted odds ratios for low-grade and high-grade prostate cancer were, respectively 0.80 [0.64-1.01] and 1.21 [0.74-1.98] for "5-ARI users" compared to "5-ARI non-users". As regard long term users ( $\geq 2$  years), a statistically significant heterogeneity ( $p = 0.0048$ ) was detected between prostate cancer grades: adjusted conditional odds ratio was 1.76 [0.97-3.21] for Gleason  $\geq 8$ , and 0.65 [0.45-0.93] for Gleason  $< 8$ . A sensitivity analysis using new Gleason grading system showed similar results (Supplementary Table S4).

## Discussion

In our study targeting subjects receiving drugs licensed for symptomatic or complicated benign prostate hypertrophy, a qualitative significant heterogeneity was observed across cancer grades when estimating association between prostate cancer and 5-ARI long term use ( $\geq 2$  years) versus no 5-ARI exposure.

Our study results differ in some important aspects of clinical setting and methodology to other observational studies(15–17) but appear in line with PCPT and REDUCE trials(4,5). Our clinical setting was more similar to the CombAT trial(14) than PCPT(4) and REDUCE trials(5). In a Finnish cohort study, risk of cancer with scores 7-10 was non-significantly increased in finasteride users compared to non-users(15). A Swedish population-based case-control study reported that an increasing duration of exposure to 5-ARI was associated with a decreased risk of Gleason scores 2-6 and 7; no significant association in risk of Gleason scores 8-10 was observed with increasing exposure time(16). Lastly, another Swedish

Accepted Article

population-based cohort study(17) reported that 5-ARI decreased the risk for prostate cancer with Gleason scores 6 and 7, and that 5-ARI did not statistically significantly affect the long-term risk of prostate cancer with Gleason scores 8-10 over a 8-year period compared to men not taking 5-ARI; more in depth, a statistically increased risk after less than 2 years of exposure to 5-ARI (HR = 1.56), became not statistically significant (HR = 1.25) with a further adjustment on PSA before treatment and there was no increased risk thereafter: authors explained that these early detected high-grade cancers were likely potential prevalent cancers, more easily diagnosed by prostate shrinkage. Of note, a one-year delay has been used to remove prevalent cancers detected due to the initial PSA test(17). Furthermore, a transient early increased risk for cancer could be related a true effect of 5-ARI selecting susceptible clones; previous studies showed no specific prostatic histologic modification in finasteride treated patients and suggested that high-grade prostate cancer could be due to the cell capacity to survive in a maybe less hormonally sensitive environment(25,26). These three observational studies used men free of prostate cancer as controls(16), compared drug users to non-users(15), or used “non 5-ARI users” as reference(17) (no details as regards BPH status or non 5-ARI BPH treatment were provided). Interestingly, Murtola’s and Robinson’s studies also assessed the association between exposure to alpha-adrenoreceptor antagonists and prostate cancer: men using alpha-adrenoreceptor antagonists had either an increased (16) or a non-significant (15) risk of low-grade prostate cancer. This result was thought to be related to a detection bias considering that men with lower urinary tract symptoms have a higher seeking of prostate cancer. Even in PCPT trial, a detection bias was put forward to explain the observed higher proportion of high-grade cancers in 5-ARI users; indeed 5-ARI decreased prostate volume (plus tumor shrinkage) and increased sensitivity of PSA. The last reassuring factor is that there is no

increased mortality rate among long-term 5-ARI users(27). Our study design did not allow to assess overall survival. Whatever, having been diagnosed with high grade prostate cancer is associated with stress and the need for treatment although the drug was initially given for a benign disease.

Our study has some strengths. First, we used a population-based nested matched case-control design which minimizes selection bias(28). Selection of eligible subjects for cohort entry was made through drug claims which were collected timely and prospectively; hence recall bias does not apply and misclassification on exposure is minimized and at least non-differential. Second, comparing treated patients, we selected subjects seeking a medical attention for symptoms justifying a drug prescription. We thought minimizing confounding by indication, compared to previous studies which used non-treated patients(4,5,15–17) as reference. Third, we thought detection bias was minimized; as PSA measurement and prostate sampling are potentially in the causal pathway leading to prostate cancer; even though no PSA results were available, the recurrence of PSA dosage and the use of prostate sampling were proxies of prostate cancer exploration; thus, we conducted a sensitivity analysis without adjustment on those parameters, showing similar results to the main analysis with full-adjustment. Fourth, we set up a two-year restriction period during which subjects had to remain free of prostate cancer diagnosis to be eligible for inclusion, reassuring us that cases were truly incident prostate cancer cases. Fifth, we had no attrition bias. Some weaknesses have to be also discussed: representativeness is more debatable than would have been a nationwide study but linkage to pathology labs imposed a restricted area. We had no information on prostate volume and body mass index but a previous study showed that such an adjustment did not materially affect the results(15). Other studies suggested that prostate volume was not related to prostate cancer risk(29) and could not be

Accepted Article

predictive of histological grade(30). We did not have information on dietary patterns but when comparing drug users between each other such healthy-user effect is thought to be less problematic. We had no valid information on family cancer status or highest level of education attained, but such an adjustment did not seem to change the results in a previous study(16). Lastly, there is a potential for exposure misclassification as regards short or mid-term users (< 2 years) because we had no claims data before 2010; on the other hand, we are confident in long-term users ( $\geq 2$  years) classification whenever observed.

The so-far rather re-assuring message as regards high-grade prostate cancer should be switched to more cautious information. Notwithstanding clear clinical benefits of 5-ARI, we should consider any substantial increased risk of high-grade cancer (worse prognosis) when choosing between therapies for symptomatic or complicated BPH. Patients treated for longer than 2 years with 5-alpha reductase inhibitors should be informed of increased risk for the development of high-grade disease.

## References

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer*. 2010 Dec 15;127(12):2893–917.
2. Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. *Eur Urol*. 2015 Oct;68(4):600–8.
3. Williamson DA, Barrett LK, Rogers BA, Freeman JT, Hadway P, Paterson DL. Infectious complications following transrectal ultrasound-guided prostate biopsy: new challenges in the era of multidrug-resistant *Escherichia coli*. *Clin Infect Dis*. 2013 Jul;57(2):267–74.
4. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. *N Engl J Med*. 2003 Jul 17;349(3):215–24.
5. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. *N Engl J Med*. 2010 Apr 1;362(13):1192–202.
6. Food and Drug Administration (FDA). Drug Safety and Availability - FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. [cited 2017 Oct 18]; Available from: <https://www.fda.gov/Drugs/DrugSafety/ucm258314.htm>
7. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. *Eur Urol*. 2013 Jul;64(1):118–40.
8. Haute Autorité de Santé (HAS). Synthèse avis de la commission de la transparence - Avodart, Chibro-Proscar, Combodart. 2012 Sep; Available from: [https://www.has-sante.fr/portail/upload/docs/application/pdf/2013-01/avodart\\_chibro\\_proscar\\_combodart\\_synthese\\_ct9291\\_9896\\_11612\\_12202\\_2013-01-21\\_10-40-28\\_852.pdf](https://www.has-sante.fr/portail/upload/docs/application/pdf/2013-01/avodart_chibro_proscar_combodart_synthese_ct9291_9896_11612_12202_2013-01-21_10-40-28_852.pdf)
9. Theoret MR, Ning Y-M, Zhang JJ, Justice R, Keegan P, Pazdur R. The risks and benefits of 5 $\alpha$ -reductase inhibitors for prostate-cancer prevention. *N Engl J Med*. 2011 Jul 14;365(2):97–9.
10. Cohen YC, Liu KS, Heyden NL, Carides AD, Anderson KM, Daifotis AG, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. *J Natl Cancer Inst*. 2007 Sep 19;99(18):1366–74.
11. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. *Cancer Prev Res Phila*. 2008 Aug;1(3):174–81.
12. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. *N Engl J Med*. 1998 Feb 26;338(9):557–63.
13. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. *N Engl J Med*. 2003 Dec 18;349(25):2387–98.

14. Roehrborn CG, Andriole GL, Wilson TH, Castro R, Rittmaster RS. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. *Eur Urol*. 2011 Feb;59(2):244–9.
15. Murtola TJ, Tammela TLJ, Määttä L, Ala-Opas M, Stenman UH, Auvinen A. Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. *Br J Cancer*. 2009 Sep 1;101(5):843–8.
16. Robinson D, Garmo H, Bill-Axelsson A, Mucci L, Holmberg L, Stattin P. Use of 5 $\alpha$ -reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. *BMJ*. 2013 Jun 18;346:f3406.
17. Wallerstedt A, Strom P, Gronberg H, Nordstrom T, Eklund M. Risk of Prostate Cancer in Men Treated With 5 $\alpha$ -Reductase Inhibitors-A Large Population-Based Prospective Study. *J Natl Cancer Inst*. 2018 Mar 14;
18. Scailteux L-M, Balusson F, Vincendeau S, Rioux-Leclercq N, Nowak E. Rationale and design of the CANARI study: a case-control study investigating the association between prostate cancer and 5-alpha-reductase inhibitors for symptomatic benign prostate hypertrophy by linking SNIIRAM and pathology laboratories in a specific region in France. *Fundam Clin Pharmacol*. 2018 Feb;32(1):120–9.
19. Palmaro A, Moulis G, Despas F, Dupouy J, Lapeyre-Mestre M. Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. *Fundam Clin Pharmacol*. 2016 Dec;30(6):616–24.
20. EAU-Guidelines-Prostate-Cancer-2010.pdf [Internet]. [cited 2018 Jun 19]. Available from: <http://uroweb.org/wp-content/uploads/EAU-Guidelines-Prostate-Cancer-2010.pdf>
21. Guidelines on prostate cancer\_EAU 2013 [Internet]. [cited 2018 Jun 19]. Available from: [http://uroweb.org/wp-content/uploads/09\\_Prostate\\_Cancer\\_LR.pdf](http://uroweb.org/wp-content/uploads/09_Prostate_Cancer_LR.pdf)
22. Cornu J-N, Cussenot O, Haab F, Lukacs B. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. *Eur Urol*. 2010 Sep;58(3):450–6.
23. Pogue J, Devereaux PJ, Thabane L, Yusuf S. Designing and analyzing clinical trials with composite outcomes: consideration of possible treatment differences between the individual outcomes. *PLoS One*. 2012;7(4):e34785.
24. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. *Eur Urol*. 2016 Mar;69(3):428–35.
25. Bostwick DG, Qian J, Civantos F, Roehrborn CG, Montironi R. Does finasteride alter the pathology of the prostate and cancer grading? *Clin Prostate Cancer*. 2004 Mar;2(4):228–35.
26. Lebdaï S, Bigot P, Azzouzi A-R. High-grade prostate cancer and finasteride. *BJU Int*. 2010 Feb;105(4):456–9.

27. Unger JM, Hershman DL, Till C, Tangen CM, Barlow WE, Ramsey SD, et al. Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial. *J Natl Cancer Inst.* 2018 Mar 9;
28. Sedgwick P. Nested case-control studies: advantages and disadvantages. *BMJ.* 2014 Feb 14;348:g1532.
29. Ankerst DP, Till C, Boeck A, Goodman P, Tangen CM, Feng Z, et al. The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator. *J Urol.* 2013 Jul;190(1):70–6.
30. Kulkarni GS, Al-Azab R, Lockwood G, Toi A, Evans A, Trachtenberg J, et al. Evidence for a biopsy derived grade artifact among larger prostate glands. *J Urol.* 2006 Feb;175(2):505–9.

**Competing interests:** All authors have completed the ICMJE uniform disclosure form at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

**Details of contributors:** LMS, EN and EO conceptualized and designed the study. Network of pathologists (and NRL) selected relevant data. LMS, FB, EN and EO analyzed the data; LMS and EO drafted the initial manuscript. All authors contributed to data interpretation, critically reviewed and revised the manuscript, and approved the final manuscript for submission. EO is the guarantor for the study. Network of pathologists: M. DOUCET; HAINRY, BROYER-PETIT & BEYLS-NOEL; COEUGNET, GIRARDOT, GOLLAIRE, TISSEAU & HOGENHUIS; PERROT, MOREAU & STAROZ; M. TAS; M. SAOUT; M. POLITIS; The authors are grateful to the CNAMTS (National Health Insurance Organization) for providing SNIIRAM data.

**Ethical approval:** The study obtained regulatory approval from CNIL (Commission Nationale Informatique et Libertés) on December 08, 2014 (authorization reference DR-2014-084; request number n°913439); a collective information about the study rather than an individual one was allowed and done through ARS Bretagne website. The patient's informed consent was not required as all the data were de-identified.

**Patients involvement:** No patients were involved on setting the research question or the outcome measure, nor they were involved in developing design of the study. No patients were asked to advise on interpretation of results. There are no plans to disseminate the results to study participants or the relevant patient community.

**Funding:** This work was supported by the Fondation pour la Recherche Médicale (FRM), grant number IMD-2013-1228948, to Emmanuel OGER and Nathalie RIOUX-LECLERCQ. FRM had no role in the study design, collection, analysis, and interpretation of data; nor in the writing of the report; nor in the decision to submit the article for publication. All investigators state their independence from funder.

**Transparency:** EO (manuscript's guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and registered) have been explained.

All authors had full access to all of the data (including statistical reports and tables) and take responsibility for the integrity of the data and the accuracy of the data analysis.

**Data sharing:** The statistical code is available from the corresponding author. Under French law and regulatory approval, patient level data cannot be made available.



## Legends

**Figure 1:** Flow chart.

**Figure 2.** Conditional adjusted odds ratios for prostate cancer.

Matching on age and delay between the first observed delivery of drug for BPH and index date through an incidence density sampling design with further adjustment on diabetes, lowering-lipid drug claims, obesity, COPD, annual number of prostate sample collection(s) (i.e., biopsy or transurethral resection) before the sample which allowed the diagnosis of cancer for cases) and annual number of PSA measurement.

p-value for heterogeneity across cancer grades (high-grade and low-grade) when estimating association between prostate cancer and 5-ARI long term use ( $\geq 2$  years) versus no 5-ARI exposure (reference) = 0.0048.

**Table 1.** Characteristics of cases (prostate cancer) and matched controls.

SD denotes standard deviation; data are number (%) of individuals unless stated otherwise.

COPD denotes chronic obstructive pulmonary disease.

(a) before index date and the date of sample which allowed the diagnosis of cancer for cases.

(b) number of prostate sample collection(s), i.e. biopsy or transurethral resection, before index date and the date of the sample which allowed the diagnosis of cancer for cases.

**Table 2.** Subjects' characteristics according to drug exposure.

(a) before index date and the date of the sample which allowed the diagnosis of cancer for cases.

(b) number of prostate sample collection(s), i.e. biopsy or transurethral resection, before index date and the date of the sample which allowed the diagnosis of cancer for cases.

**Supplementary Table S1:** ATC classification codes.

**Supplementary Table S2:** Definition of variables.

**Supplementary Table S3:** Risk of prostate cancer diagnosis.

**Supplementary Table S4:** Sensitivity analysis using new Gleason grading system.

**Table 1** Characteristics of cases (prostate cancer) and matched controls

	Overall		Gleason score of cancer			
	Cases	Controls	< 8		≥ 8	
			Cases	Controls	Cases	Controls
	N = 767	N = 3 835	N = 662	N = 3310	N = 105	N = 525
Age (years), mean (SD)	69.3 (8.6)	69.3 (8.6)	68.2 (8.1)	68.2 (8.1)	76.0 (8.5)	76.0 (8.5)
PSA measurement <sup>a</sup> , n (%)						
None	27 (3.5)	676 (17.6)	16 (2.4)	545 (16.5)	11 (10.5)	131 (25.0)
1-2	236 (30.8)	1764 (46.0)	191 (28.9)	1560 (47.1)	45 (42.9)	204 (39.9)
≥ 3	552 (72.0)	1395 (36.4)	455 (86.4)	1205 (62.5)	49 (46.7)	190 (36.2)
All prostate samples <sup>a</sup> , n (%)	767 (100)	407 (10.6)	662 (100)	357 (10.8)	105 (100)	50 (9.5)
Previous prostate biopsy <sup>b</sup> , n (%)						
None	139 (18.1)	3693 (96.3)	124 (18.8)	3183 (96.2)	15 (14.3)	510 (97.1)
1 biopsy	562 (73.3)	128 (3.3)	478 (72.2)	114 (3.4)	84 (80.0)	14 (2.7)
2 biopsies	55 (7.2)	14 (0.4)	51 (7.7)	13 (0.4)	4 (3.8)	1 (0.2)
≥ 3 biopsies	11 (1.4)	0	9 (1.4)	0	2 (1.9)	0
Transurethral resection, n (%)	195 (25.4)	256 (6.7)	163 (24.6)	219 (6.6)	32 (30.5)	37 (7.0)
COPD, n (%)	26 (3.4)	169 (4.4)	22 (3.3)	140 (4.2)	4 (3.8)	29 (5.5)
Diabetes mellitus, n (%)	91 (11.9)	532 (13.9)	69 (10.4)	454 (13.7)	22 (21.0)	78 (14.9)
Lipid-lowering drug claims, n (%)	382 (49.8)	1994 (52.0)	324 (48.9)	1704 (51.5)	58 (55.2)	290 (55.2)
Obesity, n (%)	38 (4.9)	132 (3.4)	31 (4.7)	118 (3.6)	7 (6.7)	14 (2.7)

SD denotes standard deviation; data are number (%) of individuals unless stated otherwise.

COPD denotes chronic obstructive pulmonary disease.

(a) before index date and the date of sample which allowed the diagnosis of cancer for cases.

(b) number of prostate sample collection(s), i.e. biopsy or transurethral resection, before index date and the date of the sample which allowed the diagnosis of cancer for cases.


**Table 2** *Subjects' characteristics according to drug exposure*

	5-ARI users	5-ARI non-users
	N = 963	N = 3639
Age (years), mean (SD)	71.7 (8.5)	68.6 (8.5)
PSA measurement <sup>a</sup>		
None	141 (14.6)	562 (15.4)
1-2	396 (41.1)	1604 (44.1)
≥ 3	426 (44.3)	1473 (40.5)
Previous prostate samples <sup>b</sup>		
None	827 (85.9)	3211 (88.2)
1 sample	127 (13.2)	380 (10.4)
2 samples	9 (0.9)	45 (1.2)
≥ 3 samples	0	3 (0.1)
COPD	41 (4.3)	154 (4.2)
Diabetes mellitus	125 (13.0)	498 (13.7)
Lipid-lowering drug claims	530 (55.0)	1846 (50.7)
Obesity	35 (3.6)	135 (3.7)

(a) before index date and the date of the sample which allowed the diagnosis of cancer for cases.

(b) number of prostate sample collection(s), i.e. biopsy or transurethral resection, before index date and the date of the sample which allowed the diagnosis of cancer for cases.

**Figure 1.** Flow chart.




reimbursement for a drug licensed for benign prostatic hypertrophy and free of prostate cancer in 2010-2011.

(b) non-matched samplings (n = 122 patients), inadequate matching (n = 28 patients) and 46 patients with matched sampling but without any positive examination results (Gleason score).

(c) Patients initiating treatment for symptomatic or complicated benign prostate hypertrophy within a year before index date were not eligible for the analysis.

**Figure 2.** Conditional adjusted odds ratios for prostate cancer.



Matching on age and delay between the first observed delivery of drug for BPH and index date through an incidence density sampling design with further adjustment on diabetes, lowering-lipid drug claims, obesity, COPD, annual number of prostate sample collection(s) (i.e., biopsy or transurethral resection) before the sample which allowed the diagnosis of cancer for cases) and annual number of PSA measurement.

p-value for heterogeneity across cancer grades (high-grade and low-grade) when estimating association between prostate cancer and 5-ARI long term use ( $\geq 2$  years) versus no 5-ARI exposure (reference) = 0.0048.